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Purpose: The 7th AJCC tumor node metastasis (TNM) staging system modified the classification of the lymph node metastasis widely 
compared to the 6th edition. To evaluate the prognostic predictability of the new TNM staging system, we analyzed the survival rate of 
the gastric cancer patients assessed by the 7th staging system.
Materials and Methods: Among 2,083 patients who underwent resection for gastric cancer at the department of surgery, Hanyang 
Medical Center from July 1992 to December 2009, This study retrospectively reviewed 5-year survival rate (5YSR) of 624 patients 
(TanyN3M0: 464 patients, TanyNanyM1: 160 patients) focusing on the number of metastatic lymph node and distant metastasis.  We 
evaluated the applicability of the new staging system.
Results: There were no significant differences in 5YSR between stage IIIC with more than 29 metastatic lymph nodes and stage IV 
(P=0.053). No significant differences were observed between stage IIIB with more than 28 metastatic lymph nodes and stage IV 
(P=0.093). Distinct survival differences were present between patients who were categorized as TanyN3M0 with 7 to 32 metastatic 
lymph nodes and stage IV. But patients with more than 33 metastatic lymph nodes did not show any significant differences compared 
to stage IV (P=0.055). Among patients with TanyN3M0, statistical significances were seen between patients with 7 to 30 metastatic 
lymph nodes and those with more than 31 metastatic lymph nodes. 
Conclusions: In the new staging system, modifications of N classification is mandatory to improve prognostic prediction. Further study 
involving a greater number of cases is required to demonstrate the most appropriate cutoffs for N classification.
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Introduction
According to the 6th edition of AJCC tumor node metastasis 
(TNM) staging system, cases in which the number of metastatic 
lymph node are 1~6, 7~15 and greater than 16 are determined to be 
N1, N2 and N3, respectively. Of these, TanyN3M0 is determined to 
be stage IV.(1) According to the 7th edition of AJCC TNM staging 
system, which was newly revised, cases in which the number of 
metastatic lymph node are 1~2, 3~6 and greater than 7 are deter-
mined to be N1, N2 and N3, respectively. Of these, the N3 group 
was sub-classified; cases in which the number of metastatic lymph 
node are 7~15 and greater than 16 are determined to be N3a and 
N3b, respectively. But TanyN3aM0 and TanyN3bM0 are classified 
as the same stage.(2) There are characteristics that the number of 
metastatic lymph node, based on which the N group is divided into 
N1 and N2, has a very narrow range but that, based on which it is 
classified into N3, has a very wide one. Besides, the N3 group is 
classified into stage IIb, IIIa, IIIb and IIIc although the number of 
metastatic lymph node is as the greatest can be. In various types of 
patients who were classified as the same stage, the difference in the 
survival rate should not reach a statistical significance (P＞0.05). In 
addition, if there should be a statistical significance in the differ-
Copyrights © 2011 by The Korean Gastric Cancer Association www.jgc-online.orgEvaluation of the 7th AJCC TNM Staging System
95
ence in the survival rate between the patients who were classified 
as the different stage (P＜0.05), the corresponding TNM stag-
ing system would be evaluated as appropriate. On the 6th edition, 
considering this, if the number of metastatic lymph node is greater 
than 16 (N3 based on the 6th edition of classification system), all 
the corresponding cases are classified as same stage. But there are 
problems that there was a significant difference in the survival 
rate between the group without a distant metastasis (TanyN3M0) 
which was classified as the stage IV and that (TanyNanyM1) which 
was classified as the same stage. On the 7th edition, a very simple 
classification system is applied based on the number of metastatic 
lymph node. It is necessary, however, to make a differentiation 
of and then to examine a prognosis of patients whose number of 
metastatic lymph node is very great of the groups whose number of 
metastatic lymph node is greater than 17. Besides, it would also be 
important to examine whether the new classification system might 
appropriately reflect a prognosis of the patients with gastric cancer 
based on the results of the above analysis.
Materials and Methods
Of 2,083 patients with gastric cancer who underwent gastrec-
tomy at department of surgery at Hanyang University Medical 
Center during a period ranging from July of 1992 to December of 
2009, in 464 patients without a distant metastasis with no respect 
to the degree of invasion to the gastric wall whose number of 
metastatic lymph node was greater than 7 (TanyN3M0) and 160 
patients (stage IV) who had a distant metastasis with no respect to 
the degree of invasion to the gastric wall and the degree of lymph 
node metastasis based on the degree of lymph node metastasis and 
the presence of distant metastasis, the survival rate was examined 
and the validity of TNM staging system was analyzed. Of Stage IV 
patients, there were 53 cases of sub-total gastrectomy, 51 cases of 
total gastrectomy, 27 cases of bypass surgery and 29 cases of simple 
laparotomy. In regard to the sites of distant metastasis, there were 
116 cases of peritoneal dissemination, 30 cases of hepatic metasta-
sis, six cases in which there was a concurrent presence of peritoneal 
dissemination and hepatic metastasis, two cases of Virchow’s lymph 
node metastasis, three cases of abdominal para-aortic lymph node 
metastasis and three cases in which there was a concurrent pres-
ence of Virchow’s lymph node metastasis and abdominal para-
aortic lymph node metastasis. Because there were cases in which 
there was a concurrent presence of the peritoneal dissemination, 
indications of the gastrectomy include cases in which the peritoneal 
dissemination was restricted to the proximal peritoneum around 
the stomach and those in which it was present very restrictively to 
the peritoneum below the transverse colon. In regard to cases of 
hepatic metastasis, excluding cases in which there were a very great 
number of metastatic lesions on the bilateral lobules, the systemic 
anti-cancer chemotherapy following the gastrectomy with no con-
comitant use of hepatectomy was a standard treatment regimen. In 
regard to the scope of lymph node dissection, the extensive lymph 
node dissection (D2 or higher) was performed in most of the pa-
tients (93 cases). In 11 patients whose scope of metastatic lesions 
was relatively more severe, the local lymph node dissection (D1) 
was performed. In 56 patients, the lymph node dissection was not 
performed. In our clinical series of patients, the median value of 
follow-up period was 20.5 months (the time point of final follow-
up: June 30, 2010) and the rate of follow-up was 96.6% (603/624). 
Statistical analysis was performed using SPSS ver. 13.0 (SPSS Inc., 
Chicago, IL, USA). Survival rate was calculated using a Kaplan-
Meier analysis. The difference in the survival rate was analyzed us-
ing a log-rank test in order to demonstrate a statistical significance. 
In regard to the statistical significance, a P-value of ＜0.05 was 
considered statistically significant.
Results
1. The distribution of the TNM stages in subject pa­
tients
In 464 TanyN3M0 patients who had no distant metastasis and 
whose number of metastatic lymph node was greater than 7, based 
on the distribution of the TNM stages, there were 15 cases of stage 
IIb 15, 26 cases of stage IIIa, 66 cases of stage IIIb and 357 cases of 
stage IIIc 357 (Table 1). Besides, there were 160 cases of stage IV in 
which there was a distant metastasis (M1).
Table 1. Stage distribution of TanyN3M0 gastric cancer patients
No. No. of metastatic  
LN (7~30)
No. of metastatic
LN (≥31)
Stage
T1b   15   14   1 IIb
T2   26   24   2 IIIa
T3   66    58   8 IIIb
T4a 307 256 51 IIIc
T4b   50   39 11 IIIc
Total 464 391 73
LN = lymph node.Kim SH, et al.
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2. The distribution of the survival rate depending 
on the TNM stage
In a total of 624 subject patients, there was a significant differ-
ence in the survival rate depending on the TNM stage (Table 2).
3. A comparison of the survival rate depending on 
the number of metastatic lymph node between the 
stage III and IV
Following an analysis of the difference in the survival rate 
depending on the number of metastatic lymph node in Stage IIIc 
patients as compared with stage IV ones, there was no significant 
difference in the survival rate between stage IIIc (the number of 
metastatic lymph node ＞29) and stage IV (Table 3).
There was no significant difference in the survival rate between 
Stage IIIb (the number of metastatic lymph node ＞28) and stage 
IV (Table 4).
Because there were only two Stage IIIa cases in which the 
number of metastatic lymph node was greater than 26, a statistical 
analysis could not be performed.
4. A comparison of the survival rate depending on 
the number of metastatic lymph node between the 
TanyN3M0 group and the stage IV (TanyNanyM1) 
group
Of patients with TanyN3M0, in cases in which the number of 
metastatic lymph node was 7~32, the survival rate was significantly 
higher as compared with patients with stage IV. In patients whose 
number of metastatic lymph node was greater than 33, the differ-
ence in the survival rate reached no statistical significance as com-
pared with stage IV patients (Table 5).
5. A comparison of the survival rate depending on 
the number of metastatic lymph node in the Tany 
N3M0 patient group
Of patients with TanyN3M0, there was a significant difference 
in the survival rate between the group where the number of meta-
static lymph node was 7~30 and that where it was greater than 31 
(Table 6).
Table 2. Survival rate according to the stage
Stage No. 5 YSR 
(%)
Mean±SD
(month)
P-value  
IIb   15 79.4 144.2±18.0 <0.0001
IIIa   26 66.9 107.9±12.5
IIIb   66 59.0 74.2±7.0
IIIc 357 30.8 65.8±4.6
IV 160 11.2 22.7±2.9
YSR = year survival rate; SD = standard deviation.
Table 3. Comparison of the survival rate between stage IIIc and 
stage IV according to the number of metastatic lymph nodes
Stage No. 5 YSR
(%)
Mean±SD 
(month)
P-value
Stage IIIc
  (mLN*≥27)
  79 17.1 36.5±5.8 0.017
Stage IV 160 11.2 22.7±2.9
Stage IIIc
  (mLN≥28)
  75 16.6 36.1±5.8 0.018
Stage IV 160 11.2 22.7±2.9
Stage IIIc
  (mLN≥29)
  71 12.8 32.7±5.7 0.053
Stage IV 160 11.2 22.7±2.9
Stage IIIc
  (mLN≥30)
  67 13.0 33.1±5.8 0.051
Stage IV 160 11.2 22.7±2.9
Stage IIIc
  (mLN≥31)
  62 11.3 30.2±5.6 0.126
Stage IV 160 11.2 22.7±2.9
YSR = year survival rate; SD = standard deviation. *Number of 
metastatic lymph nodes.
Table 4. Comparison of the survival rate between stage IIIb and 
stage IV according to the number of metastatic lymph nodes
Stage No.
5 YSR
(%)
Mean±SD 
(month) P-value
StageIIIb
  (mLN*≥27)
  10 30.2   45.1±13.0 0.034
Stage IV 160 11.2 22.7±2.9
Stage IIIb
  (mLN≥28)
    9 22.2   38.2±12.4 0.093
Stage IV 160 11.2 22.7±2.9
Stage IIIb
  (mLN≥32)
    8 25.0   41.3±13.6 0.075
Stage IV 160 11.2 22.7±2.9
Stage IIIb
  (mLN≥33)
    7 28.6   44.0±15.3  0.076
Stage IV 160 11.2 22.7±2.9
YSR = year survival rate; SD = standard deviation. *Number of 
metastatic lymph nodes.Evaluation of the 7th AJCC TNM Staging System
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6. A comparison of the survival rate depending on 
the number of metastatic lymph node between 
Stage IIIb, IIIc and stage IV
Following an analysis of the survival rate depending on the 
number of metastatic lymph node in patients who were classified as 
the same TNM stage, in patients with stage IIIb or stage IIIc, there 
was a significant difference in the survival rate between cases in 
which the number of metastatic lymph node was 7~30 and those 
in which it was greater than 31 (P=0.037, P＜0.0001). Of patients 
with stage IIIb and IIIc, in cases in which the number of metastatic 
lymph node was greater than 31, there was no significant difference 
in the survival rate as compared with patients with stage IV (Table 7).
Discussion
The TNM describes the anatomical scope of tumor. As shown 
in “Dukes(3) classification system” proposed for colorectal cancer 
in 1932, it was proposed based on the anatomical location of pri-
mary cancer. Thereafter, a French surgeon, Denoix(4) applied the 
TNM staging to cancers occurring in all the sites during a period 
ranging from 1943 to 1952. The stomach cancer was first included 
in the TNM staging in 1966.(5) In 1970, 1978 and 1987, the 2nd, 
the 3rd and the 4th edition were published, respectively. In 1997, on 
the 5th edition, great changes were made in the classification sys-
tem. That is, the previous classification system for the N group was 
based on the anatomical location of lymph nodes.(6) The assess-
ment of the stage of lymph nodes based on the anatomical location 
might be devoid of the accuracy. This might also lead to the de-
creased reproducibility of the assessment. This remains problematic 
when the TNM staging based on the anatomical location would be 
used as a universal method of the assessment from a worldwide 
Table 5. Comparison of the survival rate between TanyN3M0 and 
TanyNanyM1 according to the number of metastatic lymph nodes
No. 5YSR
(%)
Mean±SD 
(month)
P-value
TanyN3M0
  (mLN*≥26)
  99 18.7 39.5±5.5 0.002
TanyNanyM1 160 11.2 22.7±2.9
TanyN3M0
  (mLN≥27)
  93 19.7 40.5±5.8 0.002
TanyNanyM1 160 11.2 22.7±2.9
TanyN3M0
  (mLN≥28)
  87 17.6 38.2±5.7 0.004
TanyNanyM1 160 11.2 22.7±2.9
TanyN3M0
  (mLN≥29)
  82 14.5 35.5±5.7 0.012
TanyNanyM1 160 11.2 22.7±2.9
TanyN3M0
  (mLN≥30) 
  78 14.8 36.0±5.8 0.011
TanyNanyM1 160 11.2 22.7±2.9
TanyN3M0
  (mLN≥31)
  73 21.7 33.6±5.9 0.029
TanyNanyM1 160 11.2 22.7±2.9
TanyN3M0
  (mLN≥32)
  68 14.6 35.0±6.2 0.026
TanyNanyM1 160 11.2 22.7±2.9
TanyN3M0
  (mLN≥33)
  65 13.7 33.3±6.1 0.055
TanyNanyM1 160 11.2 22.7±2.9
TanyN3M0
  (mLN≥34)
  59 11.1 29.3±5.8 0.200
TanyNanyM1 160 11.2 22.7±2.9
YSR = year survival rate; SD = standard deviation. *Number of 
metastatic lymph nodes.
Table 6. Comparison of the survival rate in TanyN3M0 according to 
the number of metastatic lymph nodes
No. of mLN*  No.  5 YSR
(%)
Mean±SD 
(month)
P-value
7~30 391 42.4 85.0±5.1 <0.0001
≥31   73 13.4 33.6±5.7
YSR = year survival rate; SD= standard deviation. *Number of 
metastatic lymph nodes.
Table 7. Comparison of the survival rate according to the number of 
metastatic lymph nodes
Stage No.
5 YSR
(%)
Mean±
SD
(month)
P-value
Stage IIIb
  (mLN*: 7~30)
58 64.9 77.6±7.4
0.037
<0.0001 Stage IIIb
  (mLN: ≥31)
8 25.0   41.3±13.6
0.075
Stage IV 160 11.2 22.7±2.9   
Stage IIIc
  (mLN: 7~30)
295 34.8 72.0±5.3
<0.0001
<0.0001 Stage IIIc
  (mLN: ≥31)
62 11.3 30.2±5.6
0.126
Stage IV 160 11.2 22.7±2.9
YSR = year survival rate; SD= standard deviation. *Number of 
metastatic lymph nodes.Kim SH, et al.
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perspective.(7) According to the revised definition, on condition 
that a minimal number of the lymph nodes of 15 should be dis-
sected, based on the number of metastatic lymph nodes, classifica-
tions were revised to N1 (the number of metastatic lymph nodes: 
1~6), N2 (the number of metastatic lymph nodes: 7~15) and N3 
(the number of metastatic lymph nodes: ≥16).(5,8,9) Following a 
comparison between the 4th edition published in 1987 and the 5th 
edition published in 1997, Katai et al.,(10) Karpeh et al.(11) and 
Klein Kranenbarg et al.(12) reported that new classification system 
had a higher degree of applicability and predictability of the prog-
nosis as compared with previous editions of the classification sys-
tem. Mendes de Almeida et al.,(13) however, there was no signifi-
cant difference in the predictability of the prognosis between the 
two classification systems. Besides, da Manzoni et al.(14) reported 
that the number of metastatic lymph node and the anatomical lo-
cation are both independent prognostic factors. Lee et al.(15) also 
reported that there was no significant difference in the predictabili-
ty of the prognosis between the two classification systems. These 
authors were skeptical about the clarity of a cut-off point, which is 
currently used for the N classification. As described here, once the 
TNM staging system was revised, there was a variability of the as-
sessment of its usefulness depending on the authors.(16-22) There-
after, in 2002, with no changes made in the criteria for determining 
the N classification, the 6th edition of UICC/AJCC TNM classifi-
cation was reported. In 2009, the 7th edition of TNM staging sys-
tem was reported. Since January of 2010, it has been used for pa-
tients who were diagnosed with cancer.(23) Also at our medical 
institution, we reported that the 7th edition was more complicated 
than the 6th edition and there was an insufficient amount of the 
differentiation in the survival rate between the different TNM stag-
es.(24) In association with the AJCC TNM staging, controversial 
opinions have long existed regarding the N classification. On the 
6th edition of AJCC TNM staging system, cases in which the 
number of metastatic lymph nodes were 1~6, 7~15 and ≥16 were 
classified as N1, N2 and N3, respectively. Of these, the N3 was 
classified as stage IV. According to the 7th edition of AJCC TNM 
staging system which was newly revised, cases in which the num-
ber of metastatic lymph node are 1~2, 3~6 and greater than 7 are 
determined to be N1, N2 and N3, respectively. Of these, the N3 
group was sub-classified; cases in which the number of metastatic 
lymph node are 7~15 and greater than 16 are determined to be 
N3a and N3b, respectively. Because N3a and N3b classified as the 
same TNM stage, however, the new classification system is of no 
significance. Moreover, cases corresponding to N1 and N2, there is 
a narrow range of the number of metastatic lymph node (mean±
standard deviation and median value of the number of metastatic 
lymph node: N1=1.40±0.49 and 1 and N2=4.30±1.10 and 4). In 
the N3 group, however, a wider range of the number of metastatic 
lymph node was defined as compared with the 6th edition (mean±
standard deviation and median value of the number of metastatic 
lymph node=19.14±13.77, median value=15 and range=15~115). 
As described here, some cases were defined as the same TNM 
stage, although the range of the number of lymph node was too 
wide. Despite the same TNM stage, the difference in the survival 
rate based on a specific cut-off point might reach a statistical sig-
nificance. The current study was therefore conducted. Of 2,083 pa-
tients with gastric cancer who underwent gastrectomy at depart-
ment of surgery at Hanyang University Medical Center during a 
period ranging from July of 1992 to December of 2009, in 464 pa-
tients without a distant metastasis with no respect to the degree of 
invasion to the gastric wall whose number of metastatic lymph 
node was greater than 7 (TanyN3M0) and 160 patients (stage IV) 
who had a distant metastasis with no respect to the degree of inva-
sion to the gastric wall and the degree of lymph node metastasis 
based on the degree of lymph node metastasis and the presence of 
distant metastasis, the survival rate was examined and the validity 
of TNM staging system was analyzed. Following an analysis of the 
difference in the survival rate depending on the number of meta-
static lymph node in Stage IIIc patients as compared with stage IV 
ones, there was no significant difference in the survival rate be-
tween stage IIIc (the number of metastatic lymph node ＞29) and 
stage IV (P=0.053). There was no significant difference in the sur-
vival rate between Stage IIIb (the number of metastatic lymph node 
＞28) and stage IV (P=0.093). As described here, as the number of 
metastatic lymph nodes was increased between the different TNM 
stages, the difference in the survival rate between the two groups 
gradually reached no statistical significance. Because there were 
only two Stage IIIa cases in which the number of metastatic lymph 
node was greater than 26, a statistical analysis could not be per-
formed. If an analysis of the survival rate should be performed for 
a greater number of cases, however, there would be a cut-off value 
for the number of metastatic lymph nodes at which the difference 
in the survival rate reached no statistical significance even stage IIIa 
patients as compared with stage IV patients. Of patients with Tan-
yN3M0 who had no distant metastasis and whose number of met-
astatic lymph nodes was greater than 7 with no respect to the de-
gree of invasion to the gastric wall, following a comparison of the 
survival rate depending on the distribution of the number of meta-Evaluation of the 7th AJCC TNM Staging System
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static lymph nodes, in cases in which the number of metastatic 
lymph node was 7~32, the survival rate was significantly higher as 
compared with patients with stage IV. In patients whose number of 
metastatic lymph node was greater than 33, the difference in the 
survival rate reached no statistical significance as compared with 
stage IV patients. As described here, as the number of metastatic 
lymph nodes was increased, the degree of the differentiation in a 
prognosis depending on the TNM stages became obscure. In cases 
which were classified as the same TNM stage, a prognosis should 
have a consistency. In cases which were classified as the different 
TNM stage, there should be a notable difference in a prognosis. 
That is, so long as there should be similar cases from the perspec-
tives of the prognosis and treatment effect, the corresponding clas-
sification system would be evaluated as appropriate. As described 
here, if the number of metastatic lymph nodes is greater than the 
specific value despite the same stage, there would be no significant 
difference in the survival rate from the higher stage. This suggests 
that the TNM staging system could not appropriately reflect a 
prognosis of cases in which the number of metastatic lymph nodes 
was too great. Based on the results of an analysis of the N3 cases in 
the current study, following an analysis of the survival rate depend-
ing on the number of metastatic lymph node in patients who were 
classified as the same stage, in patients with stage IIIb or stage IIIc, 
there was a significant difference in the survival rate between cases 
in which the number of metastatic lymph node was 7~30 and those 
in which it was greater than 31 (P=0.037 and P＜0.0001, respec-
tively). Of patients with stage IIIb and IIIc, in cases in which the 
number of metastatic lymph node was greater than 30, there was 
no significant difference in the survival rate as compared with pa-
tients with stage IV. According to the 7th edition of AJCC staging 
system, as compared with the 6th edition, cases in which the num-
ber of metastatic lymph nodes was greater than 7 were all classiti-
fied as N3. There are also characteristics that no further higher 
TNM stages could be determined in cases in which the number of 
metastatic lymph nodes was as the greatest as can be. Based on the 
results of an analysis in the current study, however, as the number 
of metastatic lymph nodes was increased even within the same 
TNM stages, there was no significant difference in the survival rate 
as compared with the higher TNM stages. Besides, there was a sig-
nificant difference in the survival rate despite the same TNM stag-
es. As described here, the 7th edition of AJCC staging system is 
characterized by an insufficient differentiation in the survival rate 
as the number of metastatic lymph nodes became greater than a 
specific cut-off point. It can therefore be inferred that further revi-
sions are needed for the classification of lymph nodes. According 
to the 6th edition of AJCC TNM staging system, cases in which 
the number of metastatic lymph node are 1~6, 7~15 and greater 
than 16 are determined to be N1, N2 and N3, respectively. Ac-
cording to the 7th edition, however, cases in which the number of 
metastatic lymph nodes was greater than 7 were classified as the 
N3 group. In addition, following a comparison of the survival rate 
in a stepwise manner at a unit of the number of metastatic lymph 
nodes of 1 between cases which were classified as TanyN3M0 ac-
cording to the 7th edition and TanyNanyM1, the difference in the 
survival rate reached no statistical significance when the number of 
metastatic lymph nodes was greater than 33. This phenomenon was 
also observed in stage IIIb patients whose number of metastatic 
lymph nodes was greater than 28 and stage IIIc patients whose 
number of metastatic lymph nodes was greater than 29. Of the N3 
patients, however, there were only three patients with stage IIb or 
stage IIIa whose number of metastatic lymph nodes was greater 
than 24. Accordingly in these cases, a statistical analysis could not 
be performed. Based on the results of the above analysis, in cases 
which were classified as N3 according to the 7th edition, further 
efforts are needed to obtain the optimal cut-off value for the num-
ber of metastatic lymph nodes. This should be followed by sub-
classification system. Thus, efforts should be made to differentiate 
these TNM stages.
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